Navigation Links
Autoimmune disease linked to pregnancy loss, stroke more often than you’d expect
Date:11/10/2012

For years, researchers have known that antiphospholipid antibodies (aPLs) can cause pregnancy loss and clotting, but they haven't known the true scope of the problem. Now a new study provides the first estimates of the prevalence of these antibodies in patients suffering from pregnancy loss, stroke, myocardial infarction, and deep vein thrombosis.

"Based on the available data, our best estimate is that around 10 to 15% of clotting disorders are associated with autoimmune antiphospholipid antibodies," said Doruk Erkan, M.D., an associate attending rheumatologist and clinician researcher at Hospital for Special Surgery in New York City, who is the senior researcher of the study.

The research will be presented on Nov. 13, at 3:15 p.m. ET, during the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held Nov. 9-14, in Washington D.C.

In some individuals, aPLs do not cause any health problems, but in others, aPLs can trigger production of proteins that can cause inflammation and increase the risk for the formation of clots. This can cause pregnancy complications, strokes, heart attacks, and blood clots in other organs. Individuals who are aPL-positive and have either venous thrombosis, arterial thrombosis, or fetal loss are classified as having antiphospholipid syndrome (APS).

To get a grasp on the magnitude of the aPL problem, an international group of researchers searched PubMed to identify studies that involved patients with pregnancy loss, stroke, myocardial infarction or deep vein thrombosis, and that also tested patients for aPLs. They identified 108 papers and analyzed them for the type of outcome, the aPL tests used, the definition of positive aPL (low, medium, or high), confirmation of aPL, and the prevalence of positive aPL in the study population.

aPLs were found in 12% of individuals with a pregnancy loss, 14% of patients who had a stroke, 13% of patients who had a myocardial infarction, and 10% of patients who had deep vein thrombosis. Using databases that estimate the United States' prevalence of these conditions, the researchers extrapolated from their study data that aPLs are associated with approximately 60,000 cases of pregnancy loss, 120,000 cases of stroke, 120,000 cases of myocardial infarction, and 30,000 cases of deep vein thrombosis.

The researchers note that the estimates are limited by a lack of robust data. Many of the reports were old and didn't use the same classification criteria that are used today. In addition, the majority of the studies did not firmly establish the presence of aPLs in patients by performing two tests 12 weeks apart, something that is considered essential to confirm a diagnosis today. But despite the limitations, the new study does provide a rough snapshot of the prevalence of aPLs in patients with a number of health conditions.

"Accepting all of the limitations of the literature, the study does provide an estimate, which is important to raise awareness of aPLs and the health problems they cause. These numbers are also important for AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) while designing clinical trials," said Dr Erkan, who is also the executive committee chair of the newly formed clinical research organization.


'/>"/>
Contact: Phyllis Fisher
phyllis.fisher@gmail.com
212-606-1724
Hospital for Special Surgery
Source:Eurekalert

Related medicine news :

1. Statins have potential to treat an autoimmune clotting disorder called antiphospholipid syndrome
2. How infection can trigger autoimmune disease
3. New grant awards aim to prevent autoimmune diseases
4. Reactions to HIV drug have autoimmune cause, reports AIDS journal
5. Black Women With Both HIV, Hep C Less Likely to Die From Liver Disease
6. UGR and Michael J. Fox Foundation take a step forward in the study of Parkinsons disease
7. Mesothelioma drug slows disease progression in patients with an inactive NF2 gene
8. CHOP experts describe research in pediatric heart disease
9. New cell type developed for possible treatment of Alzheimers and other brain diseases
10. Looking for the anti-Alzheimers molecule -- A new approach to treating a devastating disease
11. Imaging speeds early diagnosis of heart disease, the top killer in the Western world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a digital ... digital marketing strategies of thousands of pharmacies through its ... Austin Inno,s "50 on Fire" Award in ... "We,re pleased to accept the award as one of ... Chief Executive Officer at RxWiki. "Our platform gives independent ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
Breaking Medicine Technology: